Lyncbio Therapeutics Co., Ltd.
Clinical trials sponsored by Lyncbio Therapeutics Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug LYNC-101 enters first human trials for ulcerative colitis Results expected Mar 2027 (estimated)